IgG4-related autoimmune manifestations in Alemtuzumab-treated multiple sclerosis patients
| Autor: | M. E. Evangelopoulos, Elissavet Andreadou, Dimitrios Tzanetakos, John Tzartos, Leonidas Stefanis, Georgios Koutsis, Elias Gialafos, Paraskevi Kazakou, Aigli G Vakrakou, A. Dimitrakopoulos, Nikolitsa Kafasi, Panos-Alexis Stathopoulos, Evanthia Zampeli, Dimitra Rontogianni, Eleni Lekka, George E Fragoulis, Constantinos Kilidireas, Evangelia Zapanti, Stamatios Theocharis, Maria Anagnostouli |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Hemolytic anemia Graves' disease Immunology Disease Infections medicine.disease_cause Autoimmunity Young Adult Autoimmune Diseases of the Nervous System Immune Reconstitution Multiple Sclerosis Relapsing-Remitting medicine Humans Immunology and Allergy Lymphocyte Count Adverse effect Alemtuzumab Autoantibodies Retrospective Studies Crohn's disease business.industry Multiple sclerosis Complement System Proteins medicine.disease Graves Disease Neurology Immunoglobulin G Female Neurology (clinical) business Biomarkers medicine.drug |
| Zdroj: | Journal of Neuroimmunology. 361:577759 |
| ISSN: | 0165-5728 |
| DOI: | 10.1016/j.jneuroim.2021.577759 |
| Popis: | We aimed to determine whether Alemtuzumab-induced immune reconstitution affects immunoglobulin and complement levels in the serum of Relapsing-Remitting Multiple Sclerosis (RRMS) patients. IgG4-levels were increased 24-months after treatment initiation compared to baseline levels in twenty-nine patients. Alemtuzumab-treated patients with the highest IgG4-levels were more prone to thyroid-related autoimmune manifestations and specific autoimmune adverse events such as Crohn's disease, Graves' disease, and hemolytic anemia. Compared to baseline, total IgG-levels showed a trend towards reduced levels following two-courses of Alemtuzumab, but no significant change of C3 and/or C4-levels was observed. In conclusion, monitoring of IgG4-levels can serve as a marker for secondary autoimmunity risk in multiple sclerosis patients treated with Alemtuzumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect